The case involved a clinical trial of Akero's only product, a drug candidate aimed at treating a liver disease. It's the ...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH ...

A new Equifax® (NYSE:EFX) survey shows that human resources (HR) leaders are facing challenges using technology innovation to ...

Generation IM’s Q2 2025 portfolio value declined to $15.73B, with 37 positions. Click here to read more about the portfolio's ...

Shares of Equifax Inc. EFX slid 2.06% to $248.07 Thursday, on what proved to be an all-around mixed trading session for the ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...